Skip to main navigation Skip to search Skip to main content

Parkin-Independent Mitophagy Controls Chemotherapeutic Response in Cancer Cells

  • Elodie Villa
  • , Emma Proïcs
  • , Camila Rubio-Patiño
  • , Sandrine Obba
  • , Barbara Zunino
  • , Jozef P. Bossowski
  • , Romain M. Rozier
  • , Johanna Chiche
  • , Laura Mondragón
  • , Joel S. Riley
  • , Sandrine Marchetti
  • , Els Verhoeyen
  • , Stephen W.G. Tait
  • , Jean Ehrland Ricci

Research output: Contribution to journalArticlepeer-review

274 Scopus citations

Abstract

Mitophagy is an evolutionarily conserved process that selectively targets impaired mitochondria for degradation. Defects in mitophagy are often associated with diverse pathologies, including cancer. Because the main known regulators of mitophagy are frequently inactivated in cancer cells, the mechanisms that regulate mitophagy in cancer cells are not fully understood. Here, we identified an E3 ubiquitin ligase (ARIH1/HHARI) that triggers mitophagy in cancer cells in a PINK1-dependent manner. We found that ARIH1/HHARI polyubiquitinates damaged mitochondria, leading to their removal via autophagy. Importantly, ARIH1 is widely expressed in cancer cells, notably in breast and lung adenocarcinomas; ARIH1 expression protects against chemotherapy-induced death. These data challenge the view that the main regulators of mitophagy are tumor suppressors, arguing instead that ARIH1-mediated mitophagy promotes therapeutic resistance.

Original languageEnglish
Pages (from-to)2846-2859
Number of pages14
JournalCell Reports
Volume20
Issue number12
DOIs
StatePublished - 19 Sep 2017
Externally publishedYes

Keywords

  • ARIH1
  • E3 ligase
  • PINK1
  • Parkin-independent
  • RBR-ligase
  • cell death
  • chemoresistance
  • lung cancer
  • mitophagy
  • mtKeima

Fingerprint

Dive into the research topics of 'Parkin-Independent Mitophagy Controls Chemotherapeutic Response in Cancer Cells'. Together they form a unique fingerprint.

Cite this